TLP
XENE icon

Tri Locum Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Tri Locum Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-366,102
Closed -$14.7M – 25
2025
Q3 		$14.7M Buy
+366,102
New +$12.9M 3.38% 12
2024
Q3 		– Sell
-101,959
Closed -$3.98M – 27
2024
Q2 		$3.98M Sell
101,959
-105,506
-51% -$4.22M 1.01% 20
2024
Q1 		$8.93M Sell
207,465
-18,099
-8% -$833K 3.1% 14
2023
Q4 		$10.4M Buy
225,564
+53,809
+31% +$1.9M 4.75% 11
2023
Q3 		$5.87M Buy
171,755
+147,534
+609% +$5.52M 1.88% 18
2023
Q2 		$933K Sell
24,221
-197,509
-89% -$7.85M 0.35% 37
2023
Q1 		$7.94M Buy
221,730
+128,366
+137% +$4.74M 2.42% 16
2022
Q4 		$3.68M Sell
93,364
-40,967
-30% -$1.49M 1.49% 23
2022
Q3 		$4.85M Sell
134,331
-32,068
-19% -$1.15M 1.33% 27
2022
Q2 		$5.06M Buy
+166,399
New +$5.03M 2.07% 19
2022
Q1 		– Sell
-25,043
Closed -$782K – 51
2021
Q4 		$782K Sell
25,043
-239,091
-91% -$7.14M 0.31% 37
2021
Q3 		$4.04M Buy
+264,134
New +$4.59M 1.6% 20

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Tri Locum Partners's XENE Position: Q4 2025 in Review

Tri Locum Partners sold out of Xenon Pharmaceuticals (XENE) in Q4 2025, closing a stake of 366,102 shares — an estimated $14.7M sold.

Tri Locum Partners first reported a position in XENE in Q3 2021 and held it in 12 quarters. The position peaked at $14.7M in Q3 2025. 246 funds tracked by Wall St. Rank hold XENE as of Q4 2025.

  • Tri Locum Partners reported no remaining Xenon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tri Locum Partners sold 366,102 Xenon Pharmaceuticals shares in Q4 2025, an estimated $14.7M.
  • Tri Locum Partners first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 12 quarters.
  • Tri Locum Partners's Xenon Pharmaceuticals position peaked at $14.7M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2025.

Based on Tri Locum Partners's 13F filing for Q4 2025, filed 17 Feb 2026.